Revisiting Transparency: The Role of Confidential Rebates Under Germany’s Medical Research Act
In this comprehensive report, Kintiga explores the strategic implications of this legislation for market access in Germany. Why now? Pharmaceutical […]
Insights
Navigating the Shifting Landscape of Pharmaceutical and Biotech Sectors: Insights from Industry Experts
Author: Marianne Lambertson, Chief Commercial Officer As the United States undergoes significant shifts in healthcare policy under the new administration,
NICE Severity Modifier: Misaligned with Public Perception
What is the NICE severity modifier? Author: Ben Barron-Millar, Senior Consultant In 2022, National Institute for Health and Care Excellence
Highlights from the Healixia-EUFEMED Conference 2025
Author: Brently Berx, Medical Affairs Officer This month, Kintiga BeNeLux attended the Healixia-EUFEMED joined conference in Belgium: “Mastering increasing complexity
A Global Turning Point for Rare Diseases: What the WHO Resolution Means for Biotech Innovators
Author: Sam Bryant, Regulatory Affairs Manager On 24 May 2025, the World Health Organisation (WHO) adopted a landmark resolution that
Navigating Uncertainty: The SVR’s 2025 Proposals and Their Implications for Market Access in Germany
Author: Dr. Florian Stieglitz, Market Access Consultant Germany’s statutory health insurers (GKV) face mounting deficits, now compounded by surging expenditures
EU HTA Whitepaper 2025 – One HTA Regulation for All
EU HTA: One HTA Regulation for All The strategic perspective on EU HTA from the Kintiga team For a deeper
AMNOG Report 2025: Between Innovation and Cost Control – Navigating the Future of Pharmaceutical Market Access in Germany
Author: Florian Stieglitz, Consultant The 12th edition of the AMNOG Report, recently published by DAK-Gesundheit, arrives at a decisive moment
What Trump’s MFN Executive Order Means for Pharma – A European Market Access Perspective
Author: Steve Glass , Group Chief Executive Officer This week, President Donald Trump signed a sweeping executive order that has
WODC USA 2025: Addressing Key Challenges in Orphan Drug Development
Authors: Sam Bryant, Regulatory Affairs Manager and Wim Neckebroeck, Director Regulatory Affairs At the World Orphan Drug Congress (WODC) USA
